EXEL
Price
$37.88
Change
+$0.50 (+1.34%)
Updated
Sep 5 closing price
Capitalization
10.2B
58 days until earnings call
JAZZ
Price
$129.50
Change
+$1.48 (+1.16%)
Updated
Sep 5 closing price
Capitalization
7.86B
59 days until earnings call
Interact to see
Advertisement

EXEL vs JAZZ

Header iconEXEL vs JAZZ Comparison
Open Charts EXEL vs JAZZBanner chart's image
Exelixis
Price$37.88
Change+$0.50 (+1.34%)
Volume$2.52M
Capitalization10.2B
Jazz Pharmaceuticals
Price$129.50
Change+$1.48 (+1.16%)
Volume$718.36K
Capitalization7.86B
EXEL vs JAZZ Comparison Chart in %
Loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXEL vs. JAZZ commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Hold and JAZZ is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (EXEL: $37.88 vs. JAZZ: $129.50)
Brand notoriety: EXEL: Notable vs. JAZZ: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EXEL: 80% vs. JAZZ: 98%
Market capitalization -- EXEL: $10.2B vs. JAZZ: $7.86B
EXEL [@Biotechnology] is valued at $10.2B. JAZZ’s [@Biotechnology] market capitalization is $7.86B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXEL’s FA Score shows that 0 FA rating(s) are green whileJAZZ’s FA Score has 0 green FA rating(s).

  • EXEL’s FA Score: 0 green, 5 red.
  • JAZZ’s FA Score: 0 green, 5 red.
According to our system of comparison, EXEL is a better buy in the long-term than JAZZ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXEL’s TA Score shows that 5 TA indicator(s) are bullish while JAZZ’s TA Score has 6 bullish TA indicator(s).

  • EXEL’s TA Score: 5 bullish, 2 bearish.
  • JAZZ’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, both EXEL and JAZZ are a good buy in the short-term.

Price Growth

EXEL (@Biotechnology) experienced а +1.23% price change this week, while JAZZ (@Biotechnology) price change was +1.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

EXEL is expected to report earnings on Nov 04, 2025.

JAZZ is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXEL($10.2B) has a higher market cap than JAZZ($7.86B). EXEL has higher P/E ratio than JAZZ: EXEL (18.21) vs JAZZ (15.38). EXEL YTD gains are higher at: 13.754 vs. JAZZ (5.156). EXEL has higher annual earnings (EBITDA): 782M vs. JAZZ (372M). JAZZ has more cash in the bank: 1.67B vs. EXEL (791M). EXEL has less debt than JAZZ: EXEL (180M) vs JAZZ (5.43B). JAZZ has higher revenues than EXEL: JAZZ (4.09B) vs EXEL (2.23B).
EXELJAZZEXEL / JAZZ
Capitalization10.2B7.86B130%
EBITDA782M372M210%
Gain YTD13.7545.156267%
P/E Ratio18.2115.38118%
Revenue2.23B4.09B55%
Total Cash791M1.67B47%
Total Debt180M5.43B3%
FUNDAMENTALS RATINGS
EXEL vs JAZZ: Fundamental Ratings
EXEL
JAZZ
OUTLOOK RATING
1..100
7434
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
3595
SMR RATING
1..100
3495
PRICE GROWTH RATING
1..100
5545
P/E GROWTH RATING
1..100
7476
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXEL's Valuation (68) in the Biotechnology industry is in the same range as JAZZ (70) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew similarly to JAZZ’s over the last 12 months.

EXEL's Profit vs Risk Rating (35) in the Biotechnology industry is somewhat better than the same rating for JAZZ (95) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew somewhat faster than JAZZ’s over the last 12 months.

EXEL's SMR Rating (34) in the Biotechnology industry is somewhat better than the same rating for JAZZ (95) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew somewhat faster than JAZZ’s over the last 12 months.

JAZZ's Price Growth Rating (45) in the Pharmaceuticals Other industry is in the same range as EXEL (55) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's P/E Growth Rating (74) in the Biotechnology industry is in the same range as JAZZ (76) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew similarly to JAZZ’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXELJAZZ
RSI
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
58%
Momentum
ODDS (%)
Bearish Trend 3 days ago
73%
Bullish Trend 3 days ago
68%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
64%
Bullish Trend 3 days ago
62%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
65%
Advances
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 5 days ago
60%
Declines
ODDS (%)
Bearish Trend 5 days ago
62%
Bearish Trend 28 days ago
56%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
67%
Aroon
ODDS (%)
Bullish Trend 3 days ago
58%
Bullish Trend 3 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PRAY31.230.03
+0.11%
FIS Christian Stock ETF
USTB51.100.05
+0.10%
VictoryShares Short-Term Bond ETF
LST38.470.01
+0.02%
Leuthold Select Industries ETF
EFRA34.36N/A
N/A
iShares Environmental Infras & IndstrETF
AMZY15.28-0.17
-1.10%
YieldMax AMZN Option Income Strategy ETF

EXEL and

Correlation & Price change

A.I.dvisor tells us that EXEL and LQDA have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXEL and LQDA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+1.34%
LQDA - EXEL
31%
Poorly correlated
+0.03%
JAZZ - EXEL
30%
Poorly correlated
+1.16%
RIGL - EXEL
29%
Poorly correlated
+3.02%
ACLX - EXEL
29%
Poorly correlated
+0.64%
ADCT - EXEL
29%
Poorly correlated
+4.12%
More

JAZZ and

Correlation & Price change

A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with TECH. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then TECH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAZZ
1D Price
Change %
JAZZ100%
+1.16%
TECH - JAZZ
43%
Loosely correlated
+2.82%
FTRE - JAZZ
41%
Loosely correlated
+10.66%
DAWN - JAZZ
39%
Loosely correlated
+1.89%
ROIV - JAZZ
39%
Loosely correlated
+2.78%
RGNX - JAZZ
37%
Loosely correlated
+3.08%
More